Global Blood Therapeutics Investors

20 investors on Angel Roster list Global Blood Therapeutics in their portfolio. Most are venture capital firms and hedge funds, the most common stage is Seed and the largest groups are based in the United States.

Investors are matched on the company name in their portfolio, so companies that share the name Global Blood Therapeutics can appear together.

Investors listed
20
With verified email
45%
Most common stage
Seed
Top location
United States

Updated October 13, 2026 · How we compile this data

Top 20 Global Blood Therapeutics investors

The most complete profiles first. Showing 20 of 20.

  • Adam GreeneVerified

    Hedge Fund, Venture Capital, Investor · United States

    Series BHealth CareArtificial Intelligence (AI)Information ServicesInformation Technology (IT)

    Portfolio: RubiconMD, Four Points Innovation, AveXis, CathWorks and 76 more

    Verified email available

  • Christoph LengauerVerified

    Venture Capital, Investor · United States

    SeedHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Goldfinch Biopharma, Blueprint Medicines, Magenta Therapeutics, Larimar Therapeutics and 52 more

    Verified email available

  • Craig MuirVerified

    Venture Capital, Private Equity Firm, Investor · United States

    SeedHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Goldfinch Biopharma, Blueprint Medicines, Magenta Therapeutics, Larimar Therapeutics and 52 more

    Verified email available

  • Narendra NayakVerified

    Hedge Fund, Venture Capital, Investor · United States

    Series BHealth CareArtificial Intelligence (AI)Information ServicesInformation Technology (IT)

    Portfolio: RubiconMD, Four Points Innovation, AveXis, CathWorks and 76 more

    Verified email available

  • Nicholas BishopVerified

    Hedge Fund, Venture Capital, Investment Partner · United States

    Series BHealth CareInvestment ManagementArtificial Intelligence (AI)Information Services

    Portfolio: RubiconMD, Four Points Innovation, AveXis, CathWorks and 76 more

    Verified email available

  • Robert TepperVerified

    Venture Capital, Investor · United States

    SeedHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Goldfinch Biopharma, Blueprint Medicines, Magenta Therapeutics, Larimar Therapeutics and 52 more

    Verified email available

  • Howie FurstVerified

    Hedge Fund, Investment Partner · United States

    Health CareArtificial Intelligence (AI)Information ServicesInformation Technology (IT)

    Portfolio: RubiconMD, Four Points Innovation, AveXis, CathWorks and 76 more

    Verified email available

  • Kevin BergVerified

    Hedge Fund, Investment Partner · United States

    Health CareArtificial Intelligence (AI)Information ServicesInformation Technology (IT)

    Portfolio: RubiconMD, Four Points Innovation, AveXis, CathWorks and 76 more

    Contact details available

  • Noreen RizviVerified

    Venture Capital, Private Equity Firm · United States

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Goldfinch Biopharma, Blueprint Medicines, Magenta Therapeutics, Larimar Therapeutics and 52 more

    Verified email available

  • Vincent MelletVerified

    Hedge Fund, Investment Partner · United States

    Health CareArtificial Intelligence (AI)Information ServicesInformation Technology (IT)

    Portfolio: RubiconMD, Four Points Innovation, AveXis, CathWorks and 76 more

    Verified email available

  • Abbie Celniker

    Venture Capital, Private Equity Firm, Investor · United States

    SeedHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Goldfinch Biopharma, Blueprint Medicines, Magenta Therapeutics, Larimar Therapeutics and 54 more

    Contact details available

  • Cary Pfeffer

    Venture Capital, Private Equity Firm, Investor · United States

    SeedHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Goldfinch Biopharma, Blueprint Medicines, Magenta Therapeutics, Larimar Therapeutics and 52 more

    Contact details available

  • George Xu

    Venture Capital, Investor · United States

    SeedHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Goldfinch Biopharma, Blueprint Medicines, Magenta Therapeutics, Larimar Therapeutics and 52 more

    Contact details available

  • James Flynn

    Hedge Fund, Venture Capital, Investor · United States

    Series BHealth CareInvestment ManagementArtificial Intelligence (AI)Information Services

    Portfolio: RubiconMD, Four Points Innovation, AveXis, CathWorks and 80 more

    Contact details available

  • Mark Levin

    Venture Capital, Investor · United States

    SeedHealth CareWomen FoundedLife ScienceEducation

    Portfolio: Goldfinch Biopharma, Blueprint Medicines, Magenta Therapeutics, Larimar Therapeutics and 52 more

    Contact details available

  • Neil Exter

    Venture Capital, Private Equity Firm, Investor · United States

    SeedHealth CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Goldfinch Biopharma, Blueprint Medicines, Magenta Therapeutics, Larimar Therapeutics and 52 more

    Contact details available

  • Avi Kometz

    Hedge Fund, Investment Partner · United States

    Health CareArtificial Intelligence (AI)Information ServicesInformation Technology (IT)

    Portfolio: RubiconMD, Four Points Innovation, AveXis, CathWorks and 76 more

    Contact details available

  • Kelly Moynihan

    Venture Capital · United States

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Goldfinch Biopharma, Blueprint Medicines, Magenta Therapeutics, Larimar Therapeutics and 52 more

    Contact details available

  • Walter Kowtoniuk

    Venture Capital, Private Equity Firm · United States

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Goldfinch Biopharma, Blueprint Medicines, Magenta Therapeutics, Larimar Therapeutics and 52 more

    Contact details available

  • William Motley

    Venture Capital · United States

    Health CareWomen FoundedLife ScienceBiotechnology

    Portfolio: Goldfinch Biopharma, Blueprint Medicines, Magenta Therapeutics, Larimar Therapeutics and 52 more

    Contact details available

Frequently asked questions

How many Global Blood Therapeutics investors are on Angel Roster?

Angel Roster lists 20 Global Blood Therapeutics investors. 9 of them (45%) include a verified email address.

What types of investors are they?

The most common investor types are Venture Capital Firms (16), Hedge Funds (8) and Private Equity Firms (6). An investor can have more than one type, for example an angel who is also a venture partner.

Which stages do Global Blood Therapeutics investors invest in?

Among those that list a stage, the most common are Seed (8) and Series B (4).

Where are Global Blood Therapeutics investors based?

Most are based in the United States (20).

Which companies have Global Blood Therapeutics investors backed?

The most-backed portfolio companies among them are CytomX Therapeutics (20), Element Science (20), Rhythm Metabolic (20), Constellation Pharmaceuticals (20) and Editas Medicine (20).

How do I contact Global Blood Therapeutics investors?

Create a free Angel Roster account to search and filter all 20, then unlock verified emails and LinkedIn profiles on a paid plan. Every plan starts with a 3-day free trial.